"Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]." Neuropsychiatric Disease and Treatment, , pp. 2453–2454
Disclosure
The authors report no conflicts of interest in this communication.
Neuropsychiatric Disease and Treatment
Volume 18, 2022 - Issue
LETTER
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
, 
&
Thiago Gebrin1 LIM 62, University of Sao Paulo Medical School, Sao Paulo, Brazilhttps://orcid.org/0000-0002-5145-8869
https://orcid.org/0000-0002-5145-8869 & Wellingson Silva Paiva1 LIM 62, University of Sao Paulo Medical School, Sao Paulo, BrazilCorrespondence[email protected]
https://orcid.org/0000-0002-5165-7040
https://orcid.org/0000-0002-5165-7040![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})